论文部分内容阅读
自从1906年Carnot首次发现红细胞生成素(Erythropoictin,Epo)以来,对Epo的研究已经历了将近一个世纪.但直到1978年才纯化并搞清了Epo的一级结构;1985年由Jabos和Lin分别克隆了人类Epo基因,随后Jancs和Winkelmman又成功地克隆了其受体基因。随着对Epo分子生物学认识的不断深入,特别是近十年来分子生物学理论和技术的飞速发展,使体外大规模生产重组人类红细胞生成素(rccombinant human erythropoictin,rHuEpo)成为可能,也为进一步研究Epo的组织分布、生物学作用以及为临床治疗提供了必要的手段。
Epo has been under study for almost a century since Carnot first discovered Erythropoictin (Epo) in 1906. However, it was not until 1978 that the primary structure of Epo was purified and elucidated; in 1985, Jabos and Lin Human Epo was cloned, and Jancs and Winkelmman successfully cloned their receptor genes. With the deepening of the understanding of molecular biology of Epo, especially the rapid development of molecular biology theory and technology in recent ten years, it is possible to produce recombinant human erythropoictin (rHuEpo) in large scale in vitro, To study the tissue distribution of Epo, biological effects and provide the necessary means for clinical treatment.